Comparative Pharmacology
Head-to-head clinical analysis: ANEXSIA 7 5 650 versus WYGESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANEXSIA 7 5 650 versus WYGESIC.
ANEXSIA 7.5/650 vs WYGESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
WYGESIC (ibuprofen and hydrocodone) combines a nonsteroidal anti-inflammatory drug (ibuprofen) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and a narcotic analgesic (hydrocodone) that acts as a mu-opioid receptor agonist.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
1-2 tablets (paracetamol 325 mg / tramadol 37.5 mg) orally every 4-6 hours as needed for pain, not to exceed 8 tablets per day.
None Documented
None Documented
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
3–4 hours in healthy adults; prolonged to 5–6 hours in moderate renal impairment (CrCl 30–50 mL/min) and >11 hours in severe renal impairment (CrCl <30 mL/min).
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Primarily renal: 90% as unchanged drug and glucuronide conjugate; <5% fecal.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination